Developer docs
API playgroundTry for free, no card

Search company profiles

Roche Canada

Full company profile

uuid0006l2z

Namestring
Roche Canada
Legal namestring
Hoffmann-La Roche Limited
Websiteurl
rochecanada.com
Company typeenum
Private
Founded yearint
1896
Descriptiontext

Roche Canada (legal entity Hoffmann-La Roche Limited) is the wholly-owned Canadian subsidiary of F. Hoffmann-La Roche Ltd (SIX: ROG), one of the world's largest biotech companies with a 125-year operating history and Canadian presence since 1931. Headquartered in Mississauga, Ontario with a diagnostics operations office in Laval, Quebec, the company operates two core pillars: (1) Pharmaceuticals, developing and commercializing innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, and ophthalmology, anchored by brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ and recent launches ITOVEBI (inavolisib), VABYSMO (faricimab), and TNKase (tenecteplase); and (2) Diagnostics, providing in vitro diagnostic instruments, reagents and consumables spanning clinical chemistry, immunochemistry, molecular diagnostics, hematology, histology, point-of-care testing, and next-generation sequencing. The portfolio is built on proprietary platforms including electrochemiluminescence (ECL) detection technology, the cobas pro/cobas pure integrated solutions, cobas Liat PCR point-of-care system, cobas i 601 mass spectrometry analyzer, and the navify digital solutions suite, with a parallel Diabetes Care franchise under the Accu-Chek and mySugr brands for integrated personalized diabetes management.

The company makes money through three primary revenue streams: pharmaceutical product sales reimbursed via provincial drug programs (Ontario Drug Benefit, pCPA negotiations, Ontario's FAST program), diagnostic instrument placements and recurring reagent/service contracts with hospital and reference laboratories, and hardware plus consumable sales of Accu-Chek glucose meters, test strips, and mySugr digital subscriptions through retail pharmacy and direct-to-patient channels. Go-to-market combines enterprise field sales targeting hospitals, prescribers, and lab managers with an inside-sales/call-center patient support infrastructure administered through Innomar Strategies (covering reimbursement navigation, infusion logistics, and pharmacy coordination). Customer segments span provincial and federal healthcare payers, clinical laboratories, hospital diagnostic departments, prescribers treating specialty conditions, and patients living with diabetes; major institutional relationships include the Alberta Cancer Foundation (joint $4.5M Precision Analytics Program with Pfizer and Alberta Innovates) and multiple provincial drug formularies. Pricing is not publicly disclosed and is negotiated case by case through public reimbursement channels and direct enterprise contracts.

Short descriptiontext

Roche Canada is the Canadian subsidiary of F. Hoffmann-La Roche Ltd, developing and commercializing innovative pharmaceuticals (oncology, ophthalmology, neuroscience, immunology) and a broad in vitro diagnostics portfolio (cobas platforms, point-of-care, sequencing) for hospitals, provincial payers, and patients in Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical products, in vitro diagnostics, diabetes management, oncology therapeutics, diagnostic instruments
Industry5 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKADAB
Type 1 Diabetes Care
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code4 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceuticals and In Vitro Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Products
TypeOne Time License
Description

Roche Canada (Hoffmann-La Roche Limited) develops, manufactures, and sells innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, ophthalmology, and other therapeutic areas. Revenue is generated through direct sales to hospitals, pharmacies, and healthcare providers, with public reimbursement through provincial drug programs and private insurers.

rochecanada.com
2In Vitro Diagnostic Solutions
TypeHardware Sales
Description

Roche Diagnostics develops and sells diagnostic instruments, reagents, and consumables to laboratory customers (hospitals, reference labs, point-of-care settings). Revenue comes from instrument sales, reagent contracts, and service agreements. Products span clinical chemistry, immunochemistry, molecular diagnostics, hematology, pathology, and point-of-care testing.

rochecanada.com
3Diabetes Care (Accu-Chek / mySugr)
TypeHardware Sales
Description

Roche Diabetes Care sells glucose monitoring devices, test strips, insulin delivery accessories, and digital health apps under the Accu-Chek and mySugr brands. Revenue is generated through product sales to patients, pharmacies, and healthcare institutions, with connected digital solutions enhancing patient engagement and device stickiness.

rochecanada.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Accu-Chek
Description

Brand for blood glucose monitoring systems and diabetes management solutions under Roche Diabetes Care.

rochecanada.com
+7 more records
Core offering1 text field

Roche Canada develops, manufactures, and markets innovative prescription pharmaceuticals across oncology, immunology, neuroscience, ophthalmology, infectious diseases, and rare diseases, and operates an in vitro diagnostics business supplying high-throughput laboratory analyzers, reagents, point-of-care testing systems, and digital health solutions. Diabetes care under the ACCU-CHEK and mySugr brands delivers glucose monitoring hardware and digital diabetes management apps. Patient support programs provide reimbursement navigation, infusion support, and pharmacy coordination for specialty therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Itovebi regimen more than doubled median progression-free survival compared to standard treatment alone in clinical trials for advanced HR-positive, HER2-negative breast cancer with PIK3CA mutation
+4 more records
Product overview1 text field

Roche Canada operates as a diversified healthcare company combining pharmaceuticals, diagnostics, and diabetes care. The pharmaceutical portfolio includes major brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ, and newer treatments like ITOVEBI for breast cancer, VABYSMO for ophthalmology, and TNKASE for stroke. The diagnostics business centers on the cobas integrated solutions platforms (cobas pro for high-volume and cobas pure for space-constrained labs), supplemented by point-of-care systems including CoaguChek coagulation meters, ACCU-CHEK Inform II blood glucose meters, and cobas b 101 for HbA1c/lipids. Molecular diagnostics feature the cobas Liat PCR system for decentralized testing and Sequencing Solutions for next-generation sequencing. Digital health offerings include the navify Portfolio for clinical decision support and mySugr app for diabetes management. Patient support programs provide reimbursement navigation, infusion support, and pharmacy services across therapeutic areas.

Product and service15 records
1ITOVEBI (inavolisib)
CategoryPharmaceutical - Oncology
Description

Prescription pharmaceutical indicated for adults with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation; first therapy funded through Ontario's FAST program. The Itovebi regimen more than doubled median progression-free survival versus standard treatment alone in clinical trials.

2VABYSMO (faricimab)
CategoryPharmaceutical - Ophthalmology
Description

Monoclonal antibody injection for ophthalmology treating neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion, available as pre-filled syringe and publicly funded through Ontario Drug Benefit Program.

3TNKASE (tenecteplase)
CategoryPharmaceutical - Cardiovascular/Stroke
Description

Thrombolytic agent approved by Health Canada for treatment of acute ischemic stroke in adults, demonstrating comparable safety and efficacy to alteplase in the AcT trial conducted across Canadian stroke centres.

4cobas pro integrated solutions
CategoryDiagnostic Platform - Core Laboratory
Description

High-volume integrated clinical chemistry and immunochemistry platform combining cobas c, cobas ISE neo, and cobas e 801 modules for laboratory automation, with automated maintenance, continuous reagent loading, and up to 2000 tests/hour clinical chemistry throughput using standardized reagents.

5cobas pure integrated solutions
CategoryDiagnostic Platform - Core Laboratory
Description

Compact integrated clinical chemistry, immunochemistry, and ISE testing platform on a 2m2 footprint consolidating over 230 test parameters for space-constrained laboratory settings.

6cobas i 601 Mass Spectrometry Analyzer
CategoryDiagnostic Instrument - Mass Spectrometry
Description

Fully automated, random-access, software-controlled clinical mass spectrometry analyzer integrating sample preparation, liquid chromatography, and tandem mass spectrometry (triple quadrupole with ESI ionization) on a single platform within cobas pro integrated solutions, supporting steroid hormones, vitamin D, therapeutic drug monitoring, and toxicology at up to 100 injections per hour with 48 reagent positions.

7cobas Liat Point-of-Care PCR System
CategoryDiagnostic Platform - Point-of-Care Molecular
Description

Point-of-care molecular PCR system generating high-quality results in 20 minutes or less with an evolving test menu (cobas CT/NG, CT/NG/MG, SARS-CoV-2, Influenza A/B & RSV, Strep A, Cdiff), connected via cobas POC Operations and navify Integrator for centralized management of decentralized testing environments.

8CoaguChek XS / XS Pro
CategoryDiagnostic Device - Coagulation Point-of-Care
Description

Portable point-of-care coagulation meter measuring prothrombin time and INR from a single drop of blood in under one minute, used for professional testing and patient self-testing with bidirectional cobas IT 1000 connectivity and no heparin interference at therapeutic concentrations.

9ACCU-CHEK Inform II
CategoryDiabetes Care - Hospital Meter
Description

Hospital-grade wireless blood glucose meter with 0.6 microlitre sample volume and 5-second results, featuring bidirectional cobas IT 1000 connectivity enabling real-time analysis and patient monitoring through electronic medical records.

10cobas b 101
CategoryDiagnostic Device - Point-of-Care Chemistry
Description

Compact point-of-care analyzer for HbA1c and lipid panel testing outside laboratory settings, approved in Canada for diabetes and dyslipidemia diagnosis and monitoring.

11ACCU-CHEK
CategoryDiabetes Care Consumer Brand
Description

Global brand of blood glucose monitoring systems and diabetes management products (meters, test strips, insulin delivery accessories) sold through Canadian retail pharmacies and the accu-chek.ca website as part of Roche's Integrated Personalized Diabetes Management (iPDM) open ecosystem.

12mySugr
CategoryDigital Health App
Description

Digital diabetes management app for people living with diabetes that complements ACCU-CHEK devices for logging, tracking, and therapy insights within Roche's integrated personalized diabetes management ecosystem.

13navify Digital Solutions Portfolio
CategoryDigital Health Platform
Description

Suite of digital solutions designed to enhance clinical decision-making, workflow efficiency, and operational excellence in healthcare settings, providing data integration and analysis tools across the cobas and cobas Liat installed base via cobas IT 1000 and navify Integrator.

14Roche Sequencing Solutions
CategoryDiagnostic Platform - Next-Generation Sequencing
Description

Unifying next-generation sequencing offerings that cover the entire laboratory workflow from sample isolation and preparation through sequencing technologies to bioinformatics for genetics, oncology, and other clinical research applications.

15Patient Support Programs
CategoryPatient Services - Specialty Therapy Access
Description

Programs administered through toll-free call centers and dedicated program administrators (e.g., Innomar Strategies) providing reimbursement navigation, infusion and injection support, pharmacy coordination, and ongoing patient support across oncology, immunology, neuroscience, ophthalmology, and rare disease therapeutic areas for Canadian patients on Roche specialty therapies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Pfizer joined a $4.5-million initiative alongside Roche Canada, Alberta Innovates, and the Alberta Cancer Foundation to advance cancer care in Alberta through the Precision Analytics Program. The program leverages one of the world's most complete collections of cancer data to virtually model the provincial cancer system and develop solutions to reduce wait times and improve patient outcomes.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Alberta Innovates co-funded a $4.5-million precision analytics initiative with Roche Canada, Pfizer, and the Alberta Cancer Foundation to advance cancer care in Alberta. The program was first announced in 2024 and aims to address a projected 56% rise in cancer diagnoses by 2040 through predictive analytics.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

The Alberta Cancer Foundation serves as the lead organization for the $4.5-million Precision Analytics Program, contributing funds alongside Roche Canada, Pfizer, and Alberta Innovates. The program leverages over 300 million patient visits recorded since 2014 to virtually model Alberta's cancer system and develop solutions to reduce wait times and improve outcomes.

4GovLab.ai
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-05
Description

GovLab.ai is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing predictive analytics capabilities to the initiative that leverages over 300 million patient visits of cancer data to virtually model Alberta's cancer system.

albertacancer.ca
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-05
Description

AltaML is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing machine learning and AI capabilities alongside GovLab.ai to develop solutions for reducing cancer wait times and improving patient outcomes in Alberta.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Siemens Healthineers Canada competes with Roche across in vitro diagnostics, hematology, and laboratory automation with its Atellica and Advia platforms, making it a broad-incumbent rival for hospital laboratory contracts in Canada.

2Abbott Diagnostics Canada
TypeBroad incumbent
Description

Abbott Canada is the most direct broad incumbent in Roche Diagnostics' core laboratory and immunoassay business, fielding the Architect and Alinity platforms that compete with cobas pro and cobas pure in Canadian hospitals and reference labs.

TypeDirect peer
Description

Novartis Canada is a direct peer in branded pharmaceuticals across oncology, ophthalmology, immunology, and neuroscience, competing head-to-head for provincial formulary listings and specialist prescriber share. Both companies invest heavily in Canadian real-world evidence and patient support programs.

TypeBroad incumbent
Description

J&J Canada is a broad incumbent competitor with overlapping pharma franchises in oncology, immunology, and neuroscience, plus medical devices and consumer health, making it a multi-segment competitive force rather than a single-niche peer.

TypeDirect peer
Description

Sanofi Canada is a direct peer in specialty pharmaceuticals (immunology, oncology, rare disease) and consumer health, operating with the same field-sales and reimbursement-navigation model across Canadian provinces.

TypeDirect peer
Description

Merck Canada is a direct peer in oncology (KEYTRUDA competes with TECENTRIQ), vaccines, and specialty medicines, and uses a comparable enterprise sales motion targeting Canadian hospitals, payers, and specialists.

7Bristol-Myers Squibb Canada
TypeDirect peer
Description

BMS Canada competes directly with Roche in immuno-oncology (Opdivo vs Tecentriq) and hematology, sharing the same specialty pharmacy and patient support program infrastructure for high-cost oncology biologics in Canada.

8AstraZeneca Canada
TypeDirect peer
Description

AstraZeneca Canada is a direct peer across oncology, rare disease, and cardiovascular/metabolic therapy areas, with a parallel focus on Canadian clinical trials and provincial reimbursement through the pan-Canadian Pharmaceutical Alliance.

TypeDirect peer
Description

Pfizer Canada is a direct peer with overlapping innovative pharmaceutical portfolios in oncology and rare disease and an active co-development partner of Roche Canada in the Alberta Precision Analytics Program. Both operate with similar Canadian field-sales and patient-support GTM models.

10Bayer Canada
TypeDirect peer
Description

Bayer Canada is a direct peer in pharmaceuticals (oncology, cardiology, women's health) and radiology/contrast imaging, sharing similar GTM patterns into Canadian hospitals and provincial formularies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roche Canada

Pharmaceuticals and In Vitro Diagnosticsrochecanada.com

Roche Canada is the Canadian subsidiary of F. Hoffmann-La Roche Ltd, developing and commercializing innovative pharmaceuticals (oncology, ophthalmology, neuroscience, immunology) and a broad in vitro diagnostics portfolio (cobas platforms, point-of-care, sequencing) for hospitals, provincial payers, and patients in Canada.

What Roche Canada does

Roche Canada (legal entity Hoffmann-La Roche Limited) is the wholly-owned Canadian subsidiary of F. Hoffmann-La Roche Ltd (SIX: ROG), one of the world's largest biotech companies with a 125-year operating history and Canadian presence since 1931. Headquartered in Mississauga, Ontario with a diagnostics operations office in Laval, Quebec, the company operates two core pillars: (1) Pharmaceuticals, developing and commercializing innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, and ophthalmology, anchored by brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ and recent launches ITOVEBI (inavolisib), VABYSMO (faricimab), and TNKase (tenecteplase); and (2) Diagnostics, providing in vitro diagnostic instruments, reagents and consumables spanning clinical chemistry, immunochemistry, molecular diagnostics, hematology, histology, point-of-care testing, and next-generation sequencing. The portfolio is built on proprietary platforms including electrochemiluminescence (ECL) detection technology, the cobas pro/cobas pure integrated solutions, cobas Liat PCR point-of-care system, cobas i 601 mass spectrometry analyzer, and the navify digital solutions suite, with a parallel Diabetes Care franchise under the Accu-Chek and mySugr brands for integrated personalized diabetes management.

The company makes money through three primary revenue streams: pharmaceutical product sales reimbursed via provincial drug programs (Ontario Drug Benefit, pCPA negotiations, Ontario's FAST program), diagnostic instrument placements and recurring reagent/service contracts with hospital and reference laboratories, and hardware plus consumable sales of Accu-Chek glucose meters, test strips, and mySugr digital subscriptions through retail pharmacy and direct-to-patient channels. Go-to-market combines enterprise field sales targeting hospitals, prescribers, and lab managers with an inside-sales/call-center patient support infrastructure administered through Innomar Strategies (covering reimbursement navigation, infusion logistics, and pharmacy coordination). Customer segments span provincial and federal healthcare payers, clinical laboratories, hospital diagnostic departments, prescribers treating specialty conditions, and patients living with diabetes; major institutional relationships include the Alberta Cancer Foundation (joint $4.5M Precision Analytics Program with Pfizer and Alberta Innovates) and multiple provincial drug formularies. Pricing is not publicly disclosed and is negotiated case by case through public reimbursement channels and direct enterprise contracts.

Roche Canada firmographics

Firmographics
Name
Roche Canada
Legal name
Hoffmann-La Roche Limited
Website
https://rochecanada.com
Company type
Private
Founded year
1896
Operating status
Operating
Headcount range
11–50 employees
Short description
Roche Canada is the Canadian subsidiary of F. Hoffmann-La Roche Ltd, developing and commercializing innovative pharmaceuticals (oncology, ophthalmology, neuroscience, immunology) and a broad in vitro diagnostics portfolio (cobas platforms, point-of-care, sequencing) for hospitals, provincial payers, and patients in Canada.
Ownership category
akta.pro rank

Roche Canada industry classification

Industry
Product category
Pharmaceuticals and In Vitro Diagnostics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKADAB
Type 1 Diabetes Care
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Pharmaceutical products
  • In vitro diagnostics
  • Diabetes management
  • Oncology therapeutics
  • Diagnostic instruments

Where Roche Canada is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Roche Canada business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Products: Roche Canada (Hoffmann-La Roche Limited) develops, manufactures, and sells innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, ophthalmology, and other therapeutic areas. Revenue is generated through direct sales to hospitals, pharmacies, and healthcare providers, with public reimbursement through provincial drug programs and private insurers.
  2. In Vitro Diagnostic Solutions: Roche Diagnostics develops and sells diagnostic instruments, reagents, and consumables to laboratory customers (hospitals, reference labs, point-of-care settings). Revenue comes from instrument sales, reagent contracts, and service agreements. Products span clinical chemistry, immunochemistry, molecular diagnostics, hematology, pathology, and point-of-care testing.
  3. Diabetes Care (Accu-Chek / mySugr): Roche Diabetes Care sells glucose monitoring devices, test strips, insulin delivery accessories, and digital health apps under the Accu-Chek and mySugr brands. Revenue is generated through product sales to patients, pharmacies, and healthcare institutions, with connected digital solutions enhancing patient engagement and device stickiness.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Roche Canada product offering

Product offering

Core offering

Roche Canada develops, manufactures, and markets innovative prescription pharmaceuticals across oncology, immunology, neuroscience, ophthalmology, infectious diseases, and rare diseases, and operates an in vitro diagnostics business supplying high-throughput laboratory analyzers, reagents, point-of-care testing systems, and digital health solutions. Diabetes care under the ACCU-CHEK and mySugr brands delivers glucose monitoring hardware and digital diabetes management apps. Patient support programs provide reimbursement navigation, infusion support, and pharmacy coordination for specialty therapies.

Product overview

Roche Canada operates as a diversified healthcare company combining pharmaceuticals, diagnostics, and diabetes care. The pharmaceutical portfolio includes major brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ, and newer treatments like ITOVEBI for breast cancer, VABYSMO for ophthalmology, and TNKASE for stroke. The diagnostics business centers on the cobas integrated solutions platforms (cobas pro for high-volume and cobas pure for space-constrained labs), supplemented by point-of-care systems including CoaguChek coagulation meters, ACCU-CHEK Inform II blood glucose meters, and cobas b 101 for HbA1c/lipids. Molecular diagnostics feature the cobas Liat PCR system for decentralized testing and Sequencing Solutions for next-generation sequencing. Digital health offerings include the navify Portfolio for clinical decision support and mySugr app for diabetes management. Patient support programs provide reimbursement navigation, infusion support, and pharmacy services across therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • Accu-Chek: Brand for blood glucose monitoring systems and diabetes management solutions under Roche Diabetes Care.
  • mySugr
  • cobas
  • RocheProPlus
  • VABYSMO
  • TNKase
  • Itovebi
  • navify

Products and services

  • ITOVEBI (inavolisib) Prescription pharmaceutical indicated for adults with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation; first therapy funded through Ontario's FAST program. The Itovebi regimen more than doubled median progression-free survival versus standard treatment alone in clinical trials.
  • VABYSMO (faricimab) Monoclonal antibody injection for ophthalmology treating neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion, available as pre-filled syringe and publicly funded through Ontario Drug Benefit Program.
  • TNKASE (tenecteplase) Thrombolytic agent approved by Health Canada for treatment of acute ischemic stroke in adults, demonstrating comparable safety and efficacy to alteplase in the AcT trial conducted across Canadian stroke centres.
  • cobas pro integrated solutions High-volume integrated clinical chemistry and immunochemistry platform combining cobas c, cobas ISE neo, and cobas e 801 modules for laboratory automation, with automated maintenance, continuous reagent loading, and up to 2000 tests/hour clinical chemistry throughput using standardized reagents.
  • cobas pure integrated solutions Compact integrated clinical chemistry, immunochemistry, and ISE testing platform on a 2m2 footprint consolidating over 230 test parameters for space-constrained laboratory settings.
  • cobas i 601 Mass Spectrometry Analyzer Fully automated, random-access, software-controlled clinical mass spectrometry analyzer integrating sample preparation, liquid chromatography, and tandem mass spectrometry (triple quadrupole with ESI ionization) on a single platform within cobas pro integrated solutions, supporting steroid hormones, vitamin D, therapeutic drug monitoring, and toxicology at up to 100 injections per hour with 48 reagent positions.
  • cobas Liat Point-of-Care PCR System Point-of-care molecular PCR system generating high-quality results in 20 minutes or less with an evolving test menu (cobas CT/NG, CT/NG/MG, SARS-CoV-2, Influenza A/B & RSV, Strep A, Cdiff), connected via cobas POC Operations and navify Integrator for centralized management of decentralized testing environments.
  • CoaguChek XS / XS Pro Portable point-of-care coagulation meter measuring prothrombin time and INR from a single drop of blood in under one minute, used for professional testing and patient self-testing with bidirectional cobas IT 1000 connectivity and no heparin interference at therapeutic concentrations.
  • ACCU-CHEK Inform II Hospital-grade wireless blood glucose meter with 0.6 microlitre sample volume and 5-second results, featuring bidirectional cobas IT 1000 connectivity enabling real-time analysis and patient monitoring through electronic medical records.
  • cobas b 101 Compact point-of-care analyzer for HbA1c and lipid panel testing outside laboratory settings, approved in Canada for diabetes and dyslipidemia diagnosis and monitoring.
  • ACCU-CHEK Global brand of blood glucose monitoring systems and diabetes management products (meters, test strips, insulin delivery accessories) sold through Canadian retail pharmacies and the accu-chek.ca website as part of Roche's Integrated Personalized Diabetes Management (iPDM) open ecosystem.
  • mySugr Digital diabetes management app for people living with diabetes that complements ACCU-CHEK devices for logging, tracking, and therapy insights within Roche's integrated personalized diabetes management ecosystem.
  • navify Digital Solutions Portfolio Suite of digital solutions designed to enhance clinical decision-making, workflow efficiency, and operational excellence in healthcare settings, providing data integration and analysis tools across the cobas and cobas Liat installed base via cobas IT 1000 and navify Integrator.
  • Roche Sequencing Solutions Unifying next-generation sequencing offerings that cover the entire laboratory workflow from sample isolation and preparation through sequencing technologies to bioinformatics for genetics, oncology, and other clinical research applications.
  • Patient Support Programs Programs administered through toll-free call centers and dedicated program administrators (e.g., Innomar Strategies) providing reimbursement navigation, infusion and injection support, pharmacy coordination, and ongoing patient support across oncology, immunology, neuroscience, ophthalmology, and rare disease therapeutic areas for Canadian patients on Roche specialty therapies.

Quantifiable outcome

  • Itovebi regimen more than doubled median progression-free survival compared to standard treatment alone in clinical trials for advanced HR-positive, HER2-negative breast cancer with PIK3CA mutation
  • +4 more outcomes

Companies that use Roche Canada

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Roche Canada technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

Feature9 records

Roche Canada partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • Pfizer CanadaflagshipStrategic or Co-development Partner · 5 March 2026Pfizer joined a $4.5-million initiative alongside Roche Canada, Alberta Innovates, and the Alberta Cancer Foundation to advance cancer care in Alberta through the Precision Analytics Program. The program leverages one of the world's most complete collections of cancer data to virtually model the provincial cancer system and develop solutions to reduce wait times and improve patient outcomes.
  • Alberta InnovatesflagshipStrategic or Co-development Partner · 5 March 2026Alberta Innovates co-funded a $4.5-million precision analytics initiative with Roche Canada, Pfizer, and the Alberta Cancer Foundation to advance cancer care in Alberta. The program was first announced in 2024 and aims to address a projected 56% rise in cancer diagnoses by 2040 through predictive analytics.
  • Alberta Cancer FoundationflagshipStrategic or Co-development Partner · 5 March 2026The Alberta Cancer Foundation serves as the lead organization for the $4.5-million Precision Analytics Program, contributing funds alongside Roche Canada, Pfizer, and Alberta Innovates. The program leverages over 300 million patient visits recorded since 2014 to virtually model Alberta's cancer system and develop solutions to reduce wait times and improve outcomes.
  • GovLab.aicoreTechnology or Integration · 5 March 2026GovLab.ai is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing predictive analytics capabilities to the initiative that leverages over 300 million patient visits of cancer data to virtually model Alberta's cancer system.
  • AltaMLcoreTechnology or Integration · 5 March 2026AltaML is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing machine learning and AI capabilities alongside GovLab.ai to develop solutions for reducing cancer wait times and improving patient outcomes in Alberta.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Roche Canada competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers Canada: Siemens Healthineers Canada competes with Roche across in vitro diagnostics, hematology, and laboratory automation with its Atellica and Advia platforms, making it a broad-incumbent rival for hospital laboratory contracts in Canada.
  • Abbott Diagnostics Canada: Abbott Canada is the most direct broad incumbent in Roche Diagnostics' core laboratory and immunoassay business, fielding the Architect and Alinity platforms that compete with cobas pro and cobas pure in Canadian hospitals and reference labs.
  • Johnson & Johnson Innovative Medicine Canada: J&J Canada is a broad incumbent competitor with overlapping pharma franchises in oncology, immunology, and neuroscience, plus medical devices and consumer health, making it a multi-segment competitive force rather than a single-niche peer.

Direct peers

  • Novartis Pharmaceuticals Canada: Novartis Canada is a direct peer in branded pharmaceuticals across oncology, ophthalmology, immunology, and neuroscience, competing head-to-head for provincial formulary listings and specialist prescriber share. Both companies invest heavily in Canadian real-world evidence and patient support programs.
  • Sanofi Canada: Sanofi Canada is a direct peer in specialty pharmaceuticals (immunology, oncology, rare disease) and consumer health, operating with the same field-sales and reimbursement-navigation model across Canadian provinces.
  • Merck Canada: Merck Canada is a direct peer in oncology (KEYTRUDA competes with TECENTRIQ), vaccines, and specialty medicines, and uses a comparable enterprise sales motion targeting Canadian hospitals, payers, and specialists.
  • Bristol-Myers Squibb Canada: BMS Canada competes directly with Roche in immuno-oncology (Opdivo vs Tecentriq) and hematology, sharing the same specialty pharmacy and patient support program infrastructure for high-cost oncology biologics in Canada.
  • AstraZeneca Canada: AstraZeneca Canada is a direct peer across oncology, rare disease, and cardiovascular/metabolic therapy areas, with a parallel focus on Canadian clinical trials and provincial reimbursement through the pan-Canadian Pharmaceutical Alliance.
  • Pfizer Canada: Pfizer Canada is a direct peer with overlapping innovative pharmaceutical portfolios in oncology and rare disease and an active co-development partner of Roche Canada in the Alberta Precision Analytics Program. Both operate with similar Canadian field-sales and patient-support GTM models.
  • Bayer Canada: Bayer Canada is a direct peer in pharmaceuticals (oncology, cardiology, women's health) and radiology/contrast imaging, sharing similar GTM patterns into Canadian hospitals and provincial formularies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Roche Canada social profiles

Digital presence

Roche Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roche Canada leadership team

Management profile

Number of profiles

Profiles1 record

Roche Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roche Canada M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Canada

What does Roche Canada do?

Roche Canada develops, manufactures, and markets innovative prescription pharmaceuticals across oncology, immunology, neuroscience, ophthalmology, infectious diseases, and rare diseases, and operates an in vitro diagnostics business supplying high-throughput laboratory analyzers, reagents, point-of-care testing systems, and digital health solutions. Diabetes care under the ACCU-CHEK and mySugr brands delivers glucose monitoring hardware and digital diabetes management apps. Patient support programs provide reimbursement navigation, infusion support, and pharmacy coordination for specialty therapies.

Is Roche Canada a public or private company?

Roche Canada is a private company. It is classified as corporate owned and is currently operating.

When was Roche Canada founded?

Roche Canada was founded in 1896. It employs 11 to 50 people.

Where is Roche Canada based?

Roche Canada is headquartered in Mississauga, Canada, in the North America region.

How does Roche Canada make money?

Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are in Vitro Diagnostic Solutions and diabetes Care (Accu-Chek / mySugr).

Who are Roche Canada's main competitors?

Broad incumbents on record are Siemens Healthineers Canada, Abbott Diagnostics Canada and Johnson & Johnson Innovative Medicine Canada. Direct peers are Novartis Pharmaceuticals Canada, Sanofi Canada, Merck Canada, Bristol-Myers Squibb Canada, AstraZeneca Canada, Pfizer Canada and Bayer Canada.

Does Roche Canada have an API?

No public API is recorded for Roche Canada.

What industry is Roche Canada in?

Roche Canada's product category is Pharmaceuticals and In Vitro Diagnostics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRoche Canada and Health Data Research Network Canada Announce First-of-its-Kind Partnership Focused on Pediatric Multiple Sclerosis CareRoche Canada and Health Data Research Network Canada announced a partnership to study pediatric multiple sclerosis care using health data from Alberta, Manitoba, Nova Scotia, and New Brunswick. The first initiative, the Pediatric MS Unmet Need Study, examines treatment patterns and gaps. Findings are expected to support a scientific publication and inform healthcare decision-makers.BioSpaceRoche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for Perjeta® (pertuzumab) for the neoadjuvant treatment of aggressive early stage breast cancerRoche Canada completed negotiations with the pan-Canadian Pharmaceutical Alliance for Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2-positive early breast cancer. The pCPA's August 10, 2026 deadline follows a positive CDA-AMC recommendation, bringing the drug closer to public access.BioSpaceGazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritisINESSS recommended Gazyva (obinutuzumab) for public reimbursement in Quebec for active lupus nephritis patients on standard therapy. The recommendation follows Canada's Drug Agency and Health Canada approvals, with REGENCY study data showing 46.4% complete renal response versus 33.1% on standard therapy alone.NewswireGazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritisINESSS recommended Gazyva (obinutuzumab) for public reimbursement in Quebec for active lupus nephritis patients on standard therapy. The recommendation follows Canada's Drug Agency and Health Canada approvals, with REGENCY study data showing 46.4% complete renal response versus 33.1% on standard therapy alone. Roche Canada is working with provincial jurisdictions to secure coverage.BioSpaceHealth Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapiesHealth Canada authorized Lunsumio (mosunetuzumab) and Lunsumio SC for adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The authorization covers both IV and SC formulations, based on the GO29781 study showing durable remissions. Roche Canada is working with provincial and territorial jurisdictions to ensure access.NewswireHealth Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapiesHealth Canada authorized Lunsumio (mosunetuzumab) and Lunsumio SC for adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The approval is based on the GO29781 study, which showed durable remissions, and Roche Canada is working with provinces to ensure access.NewswireGazyva® (obinutuzumab) receives positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritisCanada's Drug Agency (CDA-AMC) recommended public reimbursement of Gazyva (obinutuzumab) for adults with active lupus nephritis on May 6, 2026. The recommendation follows Health Canada's authorization and cites REGENCY study data showing 46.4% complete renal response versus 33.1% on standard therapy alone. Provincial jurisdictions will decide final reimbursement.AlbertacancerGlobal industry leaders join $4.5M initiative to advance cancer care in AlbertaPfizer, Roche Canada, and Alberta Innovates have joined the Alberta Cancer Foundation in a $4.5-million initiative to advance cancer care in Alberta through the Precision Analytics Program, which was first announced in 2024. The program leverages one of the world's most complete collections of cancer data—over 300 million patient visits recorded since 2014—to virtually model the provincial cancer system and develop solutions to reduce wait times and improve patient outcomes. With cancer diagnoses in Alberta projected to rise by 56 percent by 2040, the initiative aims to help the healthcare system stay ahead of growing demand through predictive analytics and collaboration with technology partners GovLab.ai and AltaML.NewswireItovebi® (inavolisib) marks milestone as the first breast cancer treatment funded through Ontario's new faster access programHoffmann-La Roche Limited (Roche Canada) announced that its breast cancer drug Itovebi® (inavolisib) has become the first therapy funded through Ontario's new Funding Accelerated for Specific Treatments (FAST) program, which is designed to bridge the gap between drug approval and public availability up to a full year sooner. The treatment targets adults with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, and clinical trial data showed the Itovebi regimen more than doubled median progression-free survival compared to standard treatment alone. Canada's Drug Agency issued a final positive recommendation for the treatment on December 15, 2025, and Roche Canada has indicated it is working with other jurisdictions and the pan-Canadian Pharmaceutical Alliance to expand access beyond Ontario.Signal49Value-Based Healthcare CanadaThe article discusses the establishment and activities of Value-Based Healthcare Canada (VBHC Canada), an initiative aimed at transforming Canada's healthcare system through a patient-centered, evidence-based model that emphasizes health outcomes and efficiency. The initiative leads research, coordinates implementation, and builds capacity across sectors to promote system-wide adoption of value-based healthcare, with participation from private and public stakeholders including AstraZeneca and Roche Canada.